-
HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination.
J ImmunolDanke NA, Kwok WW -
CD69-null mice protected from arthritis induced with anti-type II collagen antibodies.
Int ImmunolMurata K, Inami M, Hasegawa A, Kubo S, Kimura M, Yamashita M, Hosokawa H, Nagao T, Suzuki K, Hashimoto K, Shinkai H, Koseki H, Taniguchi M, Ziegler SF, Nakayama T -
Scurfin (FoxP3) controls T-dependent immune responses in vivo through regulation of CD4+ T cell effector function.
J ImmunolKasprowicz DJ, Smallwood PS, Tyznik AJ, Ziegler SF -
P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.
Cancer ResChikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB -
Low-avidity recognition by CD4+ T cells directed to self-antigens.
Eur J ImmunolGebe JA, Falk BA, Rock KA, Kochik SA, Heninger AK, Reijonen H, Kwok WW, Nepom GT -
Conversations with GAD.
J AutoimmunNepom GT -
Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes.
DiabetesGreenbaum CJ, Harrison LC, Immunology of Diabetes Society. -
Use of HLA class II tetramers in tracking antigen-specific T cells and mapping T-cell epitopes.
MethodsReijonen H, Kwok WW -
Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis.
Arthritis RheumSteere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT -
Differential antigen sensitivity and costimulatory requirements in human Th1 and Th2 antigen-specific CD4+ cells with similar TCR avidity.
J ImmunolHolzer U, Kwok WW, Nepom GT, Buckner JH -
HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells.
Clin ImmunolMaus MV, Riley JL, Kwok WW, Nepom GT, June CH -
MHC multimers: expanding the clinical toolkit.
Clin ImmunolNepom GT -
Challenges in staining T cells using HLA class II tetramers.
Clin ImmunolKwok WW -
Therapy of autoimmune diseases: clinical trials and new biologics.
Curr Opin ImmunolNepom GT -
Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes.
Inflamm ResHolmes JH 4th, Connolly NC, Paull DL, Hill ME, Guyton SW, Ziegler SF, Hall RA
